-DOCSTART- -X- O
Viruses -X- _ O
use -X- _ O
a -X- _ O
limited -X- _ O
set -X- _ O
of -X- _ O
host -X- _ O
pathways -X- _ O
for -X- _ O
infection. -X- _ O
These -X- _ O
pathways -X- _ O
represent -X- _ O
bona -X- _ O
fide -X- _ O
antiviral -X- _ O
targets -X- _ O
with -X- _ O
low -X- _ O
likelihood -X- _ O
of -X- _ O
viral -X- _ O
resistance. -X- _ O
We -X- _ O
identified -X- _ O
the -X- _ O
salicylanilide -X- _ B-Intervention
niclosamide -X- _ I-Intervention
as -X- _ O
a -X- _ O
broad -X- _ O
range -X- _ O
antiviral -X- _ O
agent -X- _ O
targeting -X- _ O
acidified -X- _ O
endosomes. -X- _ O
Niclosamide -X- _ B-Intervention
is -X- _ O
approved -X- _ O
for -X- _ O
human -X- _ O
use -X- _ O
against -X- _ O
helminthic -X- _ O
infections -X- _ O
, -X- _ O
and -X- _ O
has -X- _ O
anti-neoplastic -X- _ O
and -X- _ O
antiviral -X- _ O
effects. -X- _ O
Its -X- _ O
mode -X- _ O
of -X- _ O
action -X- _ O
is -X- _ O
unknown. -X- _ O
Here -X- _ O
, -X- _ O
we -X- _ O
show -X- _ O
that -X- _ O
niclosamide -X- _ B-Intervention
, -X- _ O
which -X- _ O
is -X- _ O
a -X- _ O
weak -X- _ O
lipophilic -X- _ O
acid -X- _ O
inhibited -X- _ B-Outcome
infection -X- _ I-Outcome
with -X- _ I-Outcome
pH-dependent -X- _ I-Outcome
human -X- _ I-Outcome
rhinoviruses -X- _ I-Outcome
( -X- _ I-Outcome
HRV -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
influenza -X- _ I-Outcome
virus. -X- _ I-Outcome
Structure-activity -X- _ O
studies -X- _ O
showed -X- _ O
that -X- _ O
antiviral -X- _ B-Outcome
efficacy -X- _ I-Outcome
and -X- _ I-Outcome
endolysosomal -X- _ I-Outcome
pH -X- _ I-Outcome
neutralization -X- _ I-Outcome
co-tracked -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
acidification -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
extracellular -X- _ I-Outcome
medium -X- _ I-Outcome
bypassed -X- _ I-Outcome
the -X- _ I-Outcome
virus -X- _ I-Outcome
entry -X- _ I-Outcome
block. -X- _ I-Outcome
Niclosamide -X- _ I-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
affect -X- _ I-Outcome
the -X- _ I-Outcome
vacuolar -X- _ I-Outcome
H -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
-ATPase -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
neutralized -X- _ I-Outcome
coated -X- _ I-Outcome
vesicles -X- _ I-Outcome
or -X- _ I-Outcome
synthetic -X- _ I-Outcome
liposomes -X- _ I-Outcome
, -X- _ I-Outcome
indicating -X- _ I-Outcome
a -X- _ I-Outcome
proton -X- _ I-Outcome
carrier -X- _ I-Outcome
mode-of-action -X- _ I-Outcome
independent -X- _ I-Outcome
of -X- _ I-Outcome
any -X- _ I-Outcome
protein -X- _ I-Outcome
target. -X- _ I-Outcome
This -X- _ O
report -X- _ O
demonstrates -X- _ O
that -X- _ O
physico-chemical -X- _ O
interference -X- _ O
with -X- _ O
host -X- _ O
pathways -X- _ O
has -X- _ O
broad -X- _ O
range -X- _ O
antiviral -X- _ O
effects -X- _ O
, -X- _ O
and -X- _ O
provides -X- _ O
a -X- _ O
proof -X- _ O
of -X- _ O
concept -X- _ O
for -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
host-directed -X- _ O
antivirals -X- _ O
. -X- _ O

